UBS Group’s Ibere Pharmaceuticals IBER Stock Holding History

UBS Group’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-544	Closed	-$5.49K	–	11358
2022 Q4	$5.49K	Sell	544 -1,541	-74%	-$15.4K	﹤0.01%	9175
2022 Q3	$21K	Hold	2,085	–	–	﹤0.01%	7367
2022 Q2	$20K	Hold	2,085	–	–	﹤0.01%	6912
2022 Q1	$20K	Buy	+2,085	New	+$20.3K	﹤0.01%	7485

UBS Group's IBER Position: Q1 2023 in Review

UBS Group sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 544 shares — an estimated $5.49K sold.

UBS Group first reported a position in IBER in Q1 2022 and held it in 4 quarters. The position peaked at $21K in Q3 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

UBS Group reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
UBS Group sold 544 Ibere Pharmaceuticals shares in Q1 2023, an estimated $5.49K.
UBS Group first reported a position in Ibere Pharmaceuticals in Q1 2022 and held it in 4 quarters.
UBS Group's Ibere Pharmaceuticals position peaked at $21K in Q3 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.